Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

Last updated: February 13, 2025
Sponsor: Auburn University
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

Curcumin

Epigallocatechin Gallate

Placebo

Clinical Study ID

NCT06531863
AU-STUDY00000014
  • Ages 18-50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores >9. The main questions it aims to answer are:

Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo.

Participants will consume an 8-week supplement of both:

  • 1,330mg/day curcumin

  • 350mg/day epigallocatechin gallate (EGCG)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults age 18-50

  • Depression subscale score of >9/21 on the DASS-21

  • No change in medications or supplements over the past 3 months

  • Can read and speak English

Exclusion

Exclusion Criteria:

  • Currently consume curcumin or green tea daily

  • Currently, pregnant, nursing, or trying to become pregnant

  • Currently diagnosed with a perimenopausal disorder

Study Design

Total Participants: 64
Treatment Group(s): 3
Primary Treatment: Curcumin
Phase: 1
Study Start date:
September 30, 2024
Estimated Completion Date:
August 01, 2025

Study Description

Clinical assessments will include phlebotomy (completed at weeks 0 and 8) and questionnaires which will be completed at weeks 0, 4, and 8 to assess changes in mood disorder symptomology and serum BDNF. 3 days of 24-hour diet recalls will be collected at weeks 0, 4 and 8. Daily reminders via Emitrr will be sent daily to ensure adherence to supplementation.

This is an 8-week randomized placebo controlled trial looking at mood disturbance and serum BDNF in moderately depressed adults aged 18-50. Participants will be randomized into the intervention group or placebo with the intervention group consuming 1,330mg/day curcumin and 350mg/day EGCG. Baseline mood disturbance questionnaires (DASS-21, GAD-7, GSAQ, IPAQ) and serum BDNF will be taken prior to intervention and again after intervention.

Connect with a study center

  • Auburn University School of Kinesiology

    Auburn, Alabama 36849
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.